Palvella Therapeutics (PVLA) Total Debt (2013 - 2025)
Palvella Therapeutics (PVLA) reported Total Debt of $2.2 million for Q4 2025, up 11.02% year-over-year from $2.0 million in Q4 2024, and down 0.9% on a QoQ basis from $2.2 million in Q3 2025.
Palvella Therapeutics (PVLA) has 4 years of Total Debt data on file, last reported at $2.2 million in Q4 2025.
- Quarterly Total Debt rose 11.02% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 11.02% YoY) and the FY2025 annual result came in at $2.2 million, up 11.02% from the prior year.
- Total Debt fell to $2.2 million in Q4 2025 per PVLA's latest filing, from $2.2 million in the prior quarter.
- Across five years, Total Debt topped out at $2.2 million in Q3 2025 and bottomed at $2.0 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 3,948.00 |
| Jun 30, 2014 | 948.00 |
| Mar 31, 2014 | 2,474.00 |
| Dec 31, 2013 | 1.65 Mn |
| Jun 30, 2013 | 474.00 |